BR112012012960A2 - supositório para administração retal, vaginal ou uretral e seus usos. - Google Patents

supositório para administração retal, vaginal ou uretral e seus usos.

Info

Publication number
BR112012012960A2
BR112012012960A2 BR112012012960A BR112012012960A BR112012012960A2 BR 112012012960 A2 BR112012012960 A2 BR 112012012960A2 BR 112012012960 A BR112012012960 A BR 112012012960A BR 112012012960 A BR112012012960 A BR 112012012960A BR 112012012960 A2 BR112012012960 A2 BR 112012012960A2
Authority
BR
Brazil
Prior art keywords
vaginal
rectal
suppository
urethral administration
urethral
Prior art date
Application number
BR112012012960A
Other languages
English (en)
Inventor
Heil Bettina
Original Assignee
Heil Bettina
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Heil Bettina filed Critical Heil Bettina
Publication of BR112012012960A2 publication Critical patent/BR112012012960A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A61K36/062—Ascomycota
    • A61K36/064—Saccharomycetales, e.g. baker's yeast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Abstract

pedido de patente de invenção para: supositório para administração retal, vaginal ou uretral e seus usos. a invenção se refere a um supositório para administração retal, vaginal ou uretral. a invenção também se refere ao uso de ao menos um ácido graxo insaturado não esterificado em uma composição que contenha um proibiótico e um antibiótico para a preparação de um supositório de administração retal, vaginal ou uretral.
BR112012012960A 2009-12-02 2010-12-01 supositório para administração retal, vaginal ou uretral e seus usos. BR112012012960A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09014964A EP2338476B1 (en) 2009-12-02 2009-12-02 Suppository for rectal, vaginal or urethral administration containing a probiotic, an antibiotic and an unsaturated non-esterified fatty acid
PCT/EP2010/007268 WO2011066949A1 (en) 2009-12-02 2010-12-01 Suppository for rectal, vaginal or urethral administration containing a probiotic, an antibiotic and an unsaturated non- esterified fatty acid

Publications (1)

Publication Number Publication Date
BR112012012960A2 true BR112012012960A2 (pt) 2018-05-22

Family

ID=41810070

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012012960A BR112012012960A2 (pt) 2009-12-02 2010-12-01 supositório para administração retal, vaginal ou uretral e seus usos.

Country Status (10)

Country Link
US (1) US20120237489A1 (pt)
EP (2) EP2338476B1 (pt)
JP (1) JP2013512863A (pt)
CN (1) CN102753142A (pt)
BR (1) BR112012012960A2 (pt)
CA (1) CA2782204A1 (pt)
DK (1) DK2338476T3 (pt)
ES (1) ES2388478T3 (pt)
PT (1) PT2338476E (pt)
WO (1) WO2011066949A1 (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2992861B1 (fr) 2012-07-09 2014-10-17 Probionov Utilisation de thiosulfate pour potentialiser l'effet anti-pathogene des lactobacilles
CN104434999A (zh) * 2014-11-07 2015-03-25 南昌大学 一种治疗妇女炎症的益生菌栓塞和胶囊的制备方法
BR112017024265B1 (pt) 2015-05-11 2022-08-09 Mybiotics Pharma Ltd Métodos para crescimento de um biofilme de bactérias probióticas em partículas sólidas
FR3050641B1 (fr) * 2016-04-27 2018-04-13 Biocodex Composition utile pour la preparation d’un ovule
IL294171A (en) 2016-05-25 2022-08-01 Mybiotics Pharma Ltd Compounds and methods for microbiotic therapy
EP3612570A4 (en) 2017-04-17 2021-01-13 The University of Chicago POLYMER MATERIALS FOR DELIVERING SHORT CHAIN FATTY ACIDS TO THE INTESTINAL FOR HUMAN HEALTH APPLICATIONS AND DISEASE TREATMENT
MX2019013735A (es) * 2017-05-19 2020-01-15 Lunella Biotech Inc Antimitoscinas: inhibidores especificos de la biogenesis mitocondrial para erradicar celulas madre cancerosas.
CN109010825B (zh) * 2018-08-27 2021-11-19 广州汇高生物科技有限公司 一种阴道原位凝胶制剂及其制备方法和应用
CN108653729B (zh) * 2018-08-27 2021-11-19 广州汇高生物科技有限公司 一种阴道泡沫剂及其应用
CN108853475B (zh) * 2018-09-29 2021-06-18 沈阳师范大学 一种酸化肠道抑菌栓剂及其制备方法
US10709744B1 (en) * 2019-03-28 2020-07-14 Mybiotics Pharma Ltd. Probiotic biofilm suppositories
US20220154134A1 (en) * 2019-03-28 2022-05-19 Mybiotics Pharma Ltd. Probiotic biofilm compositions and methods of preparing same
WO2022190004A1 (en) * 2021-03-10 2022-09-15 Superbrewed Food, Inc. Antibiotic-resistant probiotics and uses thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS53107408A (en) * 1977-02-28 1978-09-19 Yamanouchi Pharmaceut Co Ltd Micellar preparation for rectal infusion
JPS58140026A (ja) * 1982-01-14 1983-08-19 Toyo Jozo Co Ltd 吸収性良好な製剤
US5733568A (en) * 1993-12-03 1998-03-31 Lafor Laboratories Limited Micro-encapsulated lactobacilli for medical applications
US8828432B2 (en) * 1996-10-28 2014-09-09 General Mills, Inc. Embedding and encapsulation of sensitive components into a matrix to obtain discrete controlled release particles
US6172040B1 (en) * 1999-05-28 2001-01-09 A. Satyanarayan Naidu Immobilized lactoferrin antimicrobial agents and the use thereof
EP1212093B1 (en) * 1999-08-26 2004-07-07 Ganeden Biotech, Inc. Use of emu oil as a carrier for antifungal, antibacterial and antiviral medications
AU2003303894A1 (en) * 2003-01-30 2004-08-30 The Regents Of The University Of California Inactivated probiotic bacteria and methods of use thereof
SI1506781T1 (pt) * 2003-11-03 2005-08-31 Volkmann Peter Hansen
US20050214364A1 (en) * 2004-03-23 2005-09-29 Hutman Herbert W Products and methods for treating vaginal infections
CN1964725A (zh) * 2004-04-20 2007-05-16 芝加哥大学 包含高分子量peg－样化合物的治疗输送系统
WO2006024138A1 (en) * 2004-08-30 2006-03-09 Taro Pharmaceutical Industries Ltd. A thermoreversible pharmaceutical formulation for anti-microbial agents comprising poloxamer polymers and hydroxy fatty acid ester of polyethylene glycol
CA2579096C (en) * 2004-09-08 2012-11-13 Chelsea Therapeutics, Inc. Quinazoline derivatives as metabolically inert antifolate compounds
US20090253634A1 (en) * 2005-08-19 2009-10-08 Microbia, Inc. Methods and Compositions for the Treatment of Gastrointestinal Disorders
US20090192083A1 (en) * 2006-02-24 2009-07-30 Currie Mark G Methods and compositions for the treatment of gastrointestinal disorders

Also Published As

Publication number Publication date
EP2505188A1 (en) 2012-10-03
JP2013512863A (ja) 2013-04-18
WO2011066949A1 (en) 2011-06-09
CA2782204A1 (en) 2011-06-09
EP2338476A1 (en) 2011-06-29
EP2338476B1 (en) 2012-06-20
CN102753142A (zh) 2012-10-24
PT2338476E (pt) 2012-09-28
DK2338476T3 (da) 2012-09-17
ES2388478T3 (es) 2012-10-15
US20120237489A1 (en) 2012-09-20

Similar Documents

Publication Publication Date Title
BR112012012960A2 (pt) supositório para administração retal, vaginal ou uretral e seus usos.
AR077199A1 (es) Composicion farmaceutica y procedimiento de tratamiento para la anticoncepcion de emergencia
BR112014017650A2 (pt) composições e uso de ésteres de forbol
NI201200038A (es) Conjugados de niacina y ácidos grasos y sus usos
BRPI0806863B8 (pt) uso de um éster de forbol na preparação de um medicamento para prevenção ou tratamento de uma infecção por hiv
BRPI0801858A2 (pt) uso de pelo menos um meio de cultura celular condicionado ou de seu extrato e composiÇço cosmÉtica ou dermatolàgica
BR112015021352A2 (pt) composições antimicrobianas
CL2007001392A1 (es) Compuestos derivados de quinolina o benzopirano inhibidores de la replicacion del hiv; composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento de una infeccion por vih
CL2011002818A1 (es) Composicion de leche para el crecimiento que comprende microorganismos probioticos; uso de dicha composicion para preparar medicamento util para prevenir o tratar trastornos inflamatorios.
CL2011000214A1 (es) Composicion farmaceutica que comprende progesterona micronizada y aceite de cartamo tipo ii; y uso para el tratamiento de una condicion relacionada con la insuficiencia de secrecion de progesterona.
ECSP109917A (es) Nuevos derivados de ácido azabifenilaminobenzoico
BR112012004046A2 (pt) bifidobacterium longum e distúrbios gi funcionais.
AR075501A1 (es) Uso de inhibidores de la succinato deshidrogenasa para combatir infecciones primarias por oidio
BR112012006692A2 (pt) composição farmacêutica compreendendo ácido graxo de omega-3 e um derivado de hidróxi de uma estatina e métodos de uso das mesmas
CO6362005A2 (es) Compuestos de multiheteroarilo como inhibidores de prostaglandina d sintasa hematopoyetica y su uso para tratar enfermedades mediadas por prostaglandina d2
ECSP12011935A (es) Triazolopiridinas
CL2008003405A1 (es) Compuestos derivados de tienopiridina, inhibidores de la enzima integrasa del vih; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar una infeccion por vih.
BRPI0915536A2 (pt) salicilatos acetilados de ácidos graxos e seus usos
BRPI0911273B8 (pt) composição farmacêutica compreendendo um inibidor de dpp-iv, bem como processo para sua preparação
BR112014018421A8 (pt) Composições antimicrobianas compreendendo dgla, 15-ohepa e/ou 15-hetre e métodos de uso das mesmas
DOP2011000354A (es) Composiciones sublinguales de dexmedetomidina y metodos de uso de ellas
CL2007001648A1 (es) Compuesto derivado de leptomicina; conjugado que comprende agente de unión a células unido a uno o mas de dichos derivados; composiciones farmacéuticas que comprenden dicho derivado o conjugado; util en el tratamiento del cancer; proceso de preparacion de un compuesto o de un conjugado de un derivado de leptomicina.
UY32315A (es) Compuestos de piperidina y usos de los mismo-596
CL2011002835A1 (es) Compuestos derivados de 7-aza-espiro[3.5]nonano-7-carboxilatos; procedimiento de preparacion; compuestos intermediarios; composicion farmaceutica; y su uso para tratar dolores agudos o cronicos de tipos neurogeno, asociados a enfermedades inflamatorias, entre otros.
BRPI1009842B8 (pt) uso de agonista de tlr9 e agonista de tlr2/6 na preparação de uma composição farmacêutica para tratamento, inibição ou atenuação de uma infecção microbiana, bem como composição farmaceuticamente aceitável compreendendo os referidos agonistas

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 4A, 5A, 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2473 DE 29-05-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.